S. Wickenhauser

发表

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations

S. Chevret, B. Quesnel, E. Wattel, 2022, British journal of haematology.

Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion

T. Lavabre‐Bertrand, E. Jourdan, J. Chiésa, 2012, Leukemia & lymphoma.

Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

A. Vekhoff, E. Solary, M. Mohty, 2022, Clinical and Experimental Medicine (Testo stampato).

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

A. Vekhoff, S. Chevret, P. Fenaux, 2021, Blood.

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

S. Chevret, P. Fenaux, S. Thépot, 2022, Leukemia.

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

A. Stamatoullas, S. Chevret, B. Quesnel, 2018, Blood.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS

Stanislas, Taksin, A. Stamatoullas, 2015 .

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

S. de Botton, D. Bouscary, E. Jourdan, 2022, Blood.

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

F. Jardin, T. Petrella, E. Macintyre, 2019, Blood advances.

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

C. Preudhomme, P. Fenaux, S. Thépot, 2022, Blood.

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia

H. Dombret, T. Cluzeau, C. Récher, 2021, Leukemia & lymphoma.

Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

A. Vekhoff, E. Solary, M. Mohty, 2022, Clinical and Experimental Medicine.